Kisoji Biotechnology, Inc.

BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board, I look forward to Julie and Alan's many insights into both clinical and regulatory strategy as Elevation Oncology continues to advance its pipeline of differentiated, potentially best-in-class antibody-drug conjugate (ADC) therapies." "I am excited to lend my expertise in drug development and company building to help Elevation Oncology advance selective cancer therapies to improve the care and treatment of patients with solid tumors," said Dr. Cherrington. "With an initial update from its ongoing Phase 1 clinical trial of EO-3021 on-track for mid-year and the nomination of a HER3-ADC development candidate expected before year-end, Elevation Oncology is on the precipice of a significant transformation, and I look forward to partnering with management to thoughtfully move both programs into later stages of clinical and preclinical development, respectively." "Now is an exciting time to join Elevation Oncology," said Dr. Sandler. "In recent months, the company has focused its efforts on developing a pipeline of differentiated ADCs to address well-validated cancer targets that could potentially provide better safety and efficacy to patients living with solid tumors. I am eager to work closely with the team and to apply our collective expertise in ADC and oncology drug discovery and development to bring these novel medicines to patients with unmet needs." Dr. Cherrington is an experienced life science executive with extensive insight in bringing novel product candidates into the clinic and through to commercialization. Over the course of her career, Dr. Cherrington contributed to the successful development of multiple U.S. Food and Drug Administration-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®, and served as President and Chief Executive Officer (CEO) for several biotechnology companies. She currently serves as a Venture Partner at Brandon Capital Partners, as well as Chair of Actym Therapeutics, Chair of Tolremo Therapeutics, and director at Syncona Limited, Sardona Therapeutics, KisoJi Biotechnology and MycRx. Earlier, Dr. Cherrington served as CEO of QUE Oncology, and as President and CEO of Arch Oncology, Revitope Oncology, Inc., Zenith Epigenetics, and Pathway Therapeutics. Dr. Cherrington holds a B.S. in Biology and an M.S. in Microbiology from the University of California, Davis, and completed her Ph.D. training in Microbiology and Immunology at the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco. Dr. Sandler is an accomplished leader in oncology and drug development, with experience leading clinical development and operations, regulatory affairs, drug safety and asset development strategy across industry and academia. He currently serves as Executive Vice President and Chief Medical Officer of Mirati Therapeutics, a Bristol Myers Squibb Company. Prior to joining Mirati Therapeutics, Dr. Sandler was President and Global Head of Oncology for Zai Lab, where he led global oncology development for the company. Previously, Dr. Sandler was the Senior Vice President and Global Head, Product Development of Oncology Solid Tumors at Genentech, a member of the Roche Group. He has also held academic roles at Oregon Health and Science University, Indiana University and Vanderbilt University. Dr. Sandler holds an M.D. from Rush Medical College and completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center. He has published over 300 publications including peer-reviewed articles, reviews, abstracts and book chapters. About Elevation Oncology, Inc. Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient's unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated oncology target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are evaluating EO-3021 in a Phase 1 study in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. We are also exploring other opportunities through new or existing partnerships and business development opportunities to expand our oncology pipeline. For more information, visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of announcements of clinical results and trial details, potential benefits of Elevation Oncology's product candidates, potential market opportunities for Elevation Oncology's product candidates and the ability of Elevation Oncology's product candidates to treat their targeted indications. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "will," "would," and other words and terms of similar meaning. Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, Elevation Oncology's ability to fund development activities and achieve development goals, Elevation Oncology's ability to protect intellectual property, Elevation Oncology's ability to establish and maintain collaborations with third parties, and other risks and uncertainties described under the heading "Risk Factors" in documents Elevation Oncology files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Elevation Oncology undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Elevation Oncology Investor and Media Contact Candice Masse, 978-879-7273 Senior Director, Corporate Communications & Investor Relations [email protected] SOURCE Elevation Oncology

TOLREMO therapeutics is pioneering a differentiated approach to preventing non-genetic drug resistance in cancer Funding will accelerate the company's lead program, TT125-802, into a first-in-human study in patients with solid tumors Julie M. Cherrington has been appointed as Chair of the Board of Directors BASEL, Switzerland--(BUSINESS WIRE)-- TOLREMO therapeutics AG (TOLREMO) today announced that it has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million). BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, as well as existing investors. TOLREMO’s mission is to stop non-genetic cancer drug resistance as it emerges by dismantling cancer's earliest defenses to targeted therapies, thus surmounting a universal challenge for current and future targeted treatments. TOLREMO’s lead candidate, TT125-802, is an orally available small molecule CBP/p300 bromodomain inhibitor that blocks critical transcriptional resistance pathways responsible for cancer’s early escape mechanisms to targeted therapies. The proceeds of the Series A round will support the initiation of a Phase 1 monotherapy dose escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, and early signs of efficacy, including biological activity of TT125-802, in a range of solid tumor indications. Stepwise, TOLREMO will then advance to evaluating TT125-802 in combination with targeted therapies such as KRAS, EGFR or AR inhibitors in specific advanced solid tumor indications. "Cancer drug resistance is a major impediment to the long-term survival of patients and is most often addressed in the later stages of treatment when genetic mutations have already rendered the cancer permanently impervious to therapy. At TOLREMO, we have developed TT125-802 to specifically block early, non-genetic resistance pathways to targeted treatments. In combination with therapeutic agents, such as KRAS, EGFR, AR inhibitors, or other targeted therapies, TT125-802 has the potential to prevent therapy evasion and significantly improve treatment durability," said Stefanie Flückiger-Mangual, PhD, co-founder and Chief Executive Officer of TOLREMO. "We value the continued commitment from our current investors and warmly welcome Pierre Fabre Laboratories, the second largest private French pharmaceutical group, into our syndicate of investors through their dedicated investment body. With this strong support, we aim to advance the development of TT125-802 to bring long-term benefits to cancer patients." In conjunction with the financing, Julie M. Cherrington, PhD, an experienced life science executive with a track record of successfully bringing drugs into the clinic through to commercialization, has been appointed as Chair of the Board of Directors. In addition, Francesco Hofmann, PhD, Head of R&D for Medical Care at Pierre Fabre Laboratories, joined TOLREMO's Scientific Advisory Board. Dr. Hofmann has extensive experience in accelerating the delivery of new therapeutics, having facilitated the clinical development of more than twelve novel cancer drugs. "TOLREMO has a very distinct scientific approach to providing rational combination therapies that preemptively address the problem of drug resistance in cancer treatment. TT125-802 inhibits transcriptional changes, which are central for resistance development to a multitude of targeted cancer therapies. This new investment is very consistent with our renewed strategy to focus our R&D portfolio on targeted therapies," commented Francesco Hofmann, Head of R&D for Medical Care at Pierre Fabre Laboratories and new member of TOLREMO's Scientific Advisory Board. "I am truly impressed with TOLREMO’s achievements in discovering and advancing a highly differentiated new treatment approach originating from the analysis of non-genetic cancer resistance phenotypes," said Julie Cherrington, the new Chair of the TOLREMO Board of Directors. "I look forward to supporting the team at this critical juncture as the company advances its lead program into clinical development." Julie M. Cherrington is a seasoned biotech industry leader and holds board roles across several firms, including Mirati Therapeutics Inc, Syncona, Sardona Therapeutics, KisoJi Biotechnology, MycRx, and Actym Therapeutics, where she is also the Chair. In addition, she is a Venture Partner at Brandon Capital Partners. Dr. Cherrington has a proven track record as a company leader in her roles as CEO and R&D head at numerous companies. Furthermore, her earlier career contributions at SUGEN and Gilead Sciences were instrumental to the development of multiple FDA-approved drugs. Dr. Cherrington completed a postdoctoral fellowship at the University of California, San Francisco, and received her PhD training in microbiology and immunology from the University of Minnesota and Stanford University. She also holds a B.S. in biology and M.S. in microbiology from the University of California, Davis. About TOLREMO TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit. View source version on businesswire.com: Contacts TOLREMO therapeutics AG Dr. Stefanie Flückiger-Mangual, CEO and co-founder stefanie.flueckiger@tolremo.com Trophic Communications Stephanie May or Dr. Alison Opalko +49 (0) 151 54041130 tolremo@trophic.eu Source: TOLREMO therapeutics View this news release online at:

July 20, 2022 12:00 UTC Renowned leaders Alessandra Cesano, Julie Cherrington, and Mike Varney to serve in scientific and strategic advisor roles CAMBRIDGE, Mass.--(BUSINESS WIRE)-- GV20 Therapeutics, a biopharmaceutical company using cutting-edge genomics and artificial intelligence approaches to discover next-generation cancer therapeutics, announced the appointment of three key advisers as it prepares to advance its first drug candidate into the clinic. Appointments include Alessandra Cesano, M.D., Ph.D., current Chief Medical Officer of ESSA Pharmaceuticals; Julie Cherrington, Ph.D., a drug development expert who has served as the CEO of multiple oncology companies; and Mike Varney, Ph.D., the former head of Genentech Research and Early Development (gRED). “We are thrilled to welcome Alessandra, Julie, and Mike at this pivotal time for our company,” said Shirley Liu, CEO of GV20. “Our advisers are some of the most respected and accomplished leaders in oncology, with a wealth of experience building companies and translating innovative science into medicines for patients. Their recruitment speaks to the promise of our integrated STEAD genomics and AI platform. Their guidance will be a critical asset for us as we advance XBH25 towards the clinic and work to expand our pipeline.” ABOUT ALESSANDRA CESANO, M.D., PH.D. Alessandra Cesano, M.D., Ph.D., currently serves as the Chief Medical Officer of ESSA Pharmaceuticals. Prior to joining ESSA, Dr. Cesano was Chief Medical Officer at NanoString Technologies, Inc., Cleave Biosciences, Inc., and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the research and development group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec, and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late-stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR, and SITC. In the latter she serves as co-chair in the SITC Industry Committee, associate editor for the biomarker section of JITC, and is an active member of the SITC Biomarker Working Group. Over her career she has authored over 100 publications. Dr. Cesano received an M.D. summa cum laude, a board certification in oncology, and a Ph.D. in tumor immunology from the University of Turin (Turin, Italy). ABOUT JULIE CHERRINGTON, PH.D. Julie M. Cherrington, Ph.D., is an experienced life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®. Dr. Cherrington is also an experienced company builder – she has served as President and CEO at several biotechnology companies, including QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation, a diabetes and antiviral company. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She received her Ph.D. training in microbiology and immunology from the University of Minnesota and Stanford University and completed a postdoctoral fellowship at the University of California, San Francisco. Dr. Cherrington is active in entrepreneurship initiatives through CLS, UC San Francisco, UC Davis, and Equalize (2020, 2021, 2022). Currently, she is a Venture Partner at Brandon Capital Partners and serves on the Boards of Syncona Ltd, Sardona Therapeutics, KisoJi Biotechnology, MycRx, Vaxart, Mirati Therapeutics, and Actym Therapeutics (Chair). ABOUT MIKE VARNEY, PH.D. Mike Varney, Ph.D., is a pioneer drug discoverer and biotech leader. As one of the original fifteen employees at Agouron, a biotech based in San Diego, he built a team that developed protein-structure based design, a novel approach to drug discovery that is utilized globally by drug discovery teams today. In 1997, the Agouron team launched Viracept®, an HIV protease inhibitor that achieved the highest first year launch sales of any biotech product at the time. Dr. Varney’s leadership at Agouron resulted in the discovery of a number of currently marketed anti-cancer agents, including Xalkori® and Inlyta®, a drug that won the American Chemical Society’s Heroes of Chemistry Award in 2018. In 2005, Dr. Varney was recruited to Genentech to expand the organization’s drug discovery capabilities to include small molecules. Focused on agility and pioneering science, Dr. Varney built a team-based organization that today produces more than 40% of Genentech’s development portfolio, including the marketed anti-cancer agents Erivedge® and Cotellic®. In 2015, Dr. Varney was appointed Executive Vice President and Head of Genentech Research and Early Development (gRED) and a member of the Roche Corporate Executive Committee. In this role, he was responsible for all aspects of gRED innovation, drug discovery, and development. Dr. Varney also focused on building a team-based culture empowered to clear the path to patients. Under his leadership, gRED teams discovered and developed successful medicines that include Venclexta® with AbbVie, the first BCL-2 inhibitor, Polivy®, an antibody drug conjugate for the treatment of DLBCL, and Lunsumio, a first-in-class CD20xCD3 T-cell engaging bispecific antibody. Pioneering molecules in clinical development include GDC-9545, a next-generation estrogen receptor degrader, tiragolumab, a novel immune checkpoint inhibitor, and GDC-0077, a selective PI3Kα inhibitor. Dr. Varney retired from Genentech in July 2020, leaving a diversity of drug platform types that includes personalized therapeutic vaccines and cellular therapies. Dr. Varney holds a B.S. in chemistry from the University of California, Los Angeles, and a Ph.D. in synthetic organic chemistry from the California Institute of Technology, and was an American Cancer Society postdoctoral fellow at Columbia University. Dr. Varney is currently an advisor and Board member for several private and public biotechnology companies. ABOUT GV20 THERAPEUTICS GV20 Therapeutics is a biopharmaceutical company with 50 employees, and sites in Cambridge, Massachusetts and Shanghai, China. The company closed a Series B financing led by Coatue Management in October 2021. GV20 uses high-throughput functional genomics and artificial intelligence to identify novel cancer immunology drug targets and antibody therapeutics. The company’s pipeline includes XBH25, a novel NK checkpoint inhibitor targeting solid tumors, which is currently progressing toward the clinic. “GV20” references one of the most important acupoints for the human body, symbolizing the company’s mission to find and exploit vulnerabilities in cancer biology. To learn more about GV20, please visit and follow the company on LinkedIn and Twitter.